Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
The Company noted that the delay is due to logistical issues and isunrelated to any significant changes in the Company's financial condition,results of operations or in the effectiveness of the Company's internalcontrols. The Company will issue a subsequent announcement regarding the newdate and time of its earnings release and conference call within the nextweek.
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the treatment ofcardiovascular disease and is a leader in devices that stimulate cardiacangiogenesis. The company's market leading Holmium: YAG laser system anddisposable fiber-optic accessories are used to perform a FDA-cleared surgicalprocedure known as Transmyocardial Revascularization (TMR) to treat patientssuffering from angina. Surgical products and accessories for the CardiogenesisTMR procedure, which are marketed in the U.S. and around the world, have beenshown to reduce angina and improve the quality of life in patients withcoronary artery disease. Surgical products and accessories for the company'sminimally invasive Percutaneous Myocardial Channeling (PMC) procedure arecurrently being marketed in Europe and other international markets.
For more information on the company and its products, please visit theCardiogenesis company website at http://www.cardiogenesis.com or the direct topatient website at http://www.heartofnewlife.com.
Cardiogenesis Corporation, +1-949-420-1800
SOURCE Cardiogenesis Corporation
You May Also Like